Fluperlapine

Fluperlapine
Clinical data
ATC code	none;
Identifiers
	IUPAC name 3-fluoro-6-(4-methylpiperazin-1-yl)-11H-dibenzo[b,e]azepine;
CAS Number	67121-76-0 ;
PubChem CID	49381;
ChemSpider	44882 ;
UNII	EWG253M961;
ChEMBL	ChEMBL63756 ;
CompTox Dashboard (EPA)	DTXSID2046123 ;
Chemical and physical data
Formula	C19H20FN3
Molar mass	309.388 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc4ccc3c(/N=C(/N1CCN(C)CC1)c2ccccc2C3)c4;
	InChI InChI=1S/C19H20FN3/c1-22-8-10-23(11-9-22)19-17-5-3-2-4-14(17)12-15-6-7-16(20)13-18(15)21-19/h2-7,13H,8-12H2,1H3 ; Key:OBWGMKKHCLHVIE-UHFFFAOYSA-N ;
	(what is this?) (verify)

Fluperlapine (NB 106-689), also known as fluoroperlapine, is a morphanthridine (11H-dibenzo[b,e]azepine) atypical antipsychotic with additional antidepressant and sedative effects. It was first synthesized in 1979, and then subsequently studied in animals and humans in 1984 and beyond,^[1] but despite demonstrating efficacy in the treatment of a variety of medical conditions including schizophrenia,^[2]^[3]^[4]^[5] psychosis associated with Parkinson's disease,^[6] depressive symptoms, and dystonia,^[7] it was never marketed.^[1] This was perhaps due to its capacity for producing potentially life-threatening agranulocytosis, similarly to clozapine,^[8] which it closely resembles both structurally and pharmacologically.

Quick Facts Clinical data, ATC code ...

Pharmacology